This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
New Strong Sell Stocks for July 16th
by Zacks Equity Research
ALB, AAL and AQST have been added to the Zacks Rank #5 (Strong Sell) List on July 16, 2024.
ALBNegative Net Change AALNegative Net Change AQSTPositive Net Change
industrial-products medical transportation
New Strong Buy Stocks for July 16th
by Zacks Equity Research
BTG, APOG, AZTA, AFYA and KGC have been added to the Zacks Rank #1 (Strong Buy) List on July 16, 2024.
KGCNegative Net Change APOGNegative Net Change BTGNegative Net Change AFYANegative Net Change AZTANegative Net Change
consumer-discretionary gold industrial-products medical
The Zacks Analyst Blog DexCom, Hologic, Alcon Intuitive Surgical and Thermo Fisher Scientific
by Zacks Equity Research
DexCom, Hologic, Alcon Intuitive Surgical and Thermo Fisher Scientific are included in this Analyst Blog.
ISRGPositive Net Change TMONegative Net Change HOLXPositive Net Change ALCPositive Net Change DXCMPositive Net Change
medical
Q2 Earnings Season Scorecard and Analyst Reports for Microsoft, Eli Lilly & UnitedHealth
by Sheraz Mian
Today's Research Daily features a real-time update on the Q2 earnings season and new research reports on Microsoft (MSFT), Eli Lilly (LLY) and UnitedHealth (UNH), as well as a micro-cap stock Tile Shop Holdings (TTSH).
LMTNegative Net Change MSFTNegative Net Change UNHPositive Net Change LLYPositive Net Change INFYNegative Net Change MCKPositive Net Change TTSHNegative Net Change
computers medical pharmaceuticals retail
Myriad Genetics (MYGN) Expands in MRD Testing With New Collab
by Zacks Equity Research
Myriad Genetics (MYGN) inks an agreement with Personalis to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease. The idea is to broaden patient access to the benefits of MRD testing.
HAEPositive Net Change MYGNNegative Net Change AHCONegative Net Change HIMSNegative Net Change
medical
Patterson Companies (PDCO) Aims to Streamline Patient Experience
by Zacks Equity Research
Patterson Companies' (PDCO) latest integration features are likely to provide customers with additional options to streamline their experience.
SYKPositive Net Change DVAPositive Net Change PDCONegative Net Change ELVNegative Net Change
medical medical-devices
Terumo (TRUMY) Unit's SOFAST Study Shows Positive Results
by Zacks Equity Research
Terumo (TRUMY) subsidiary Microvention's SOFAST study validates the SOFIA Flow Plus Aspiration Catheter's speed, efficacy and safety in stroke thrombectomy.
UHSNegative Net Change DVAPositive Net Change DXCMPositive Net Change TRUMYNegative Net Change
medical medical-devices
Novo Nordisk (NVO) GLP-1 Drug Regarded Safe for Brain by Oxford
by Zacks Equity Research
Oxford study demonstrates that Novo Nordisk's (NVO) semaglutide is not associated with a risk of adverse neuropsychiatric outcomes compared with other antidiabetic medications over one year.
BIIBPositive Net Change NVOPositive Net Change LLYPositive Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Alcon (ALC) Rides on Innovation, Balanced Segmental Sales
by Zacks Equity Research
Alcon (ALC) is witnessing growth in its over-the-counter portfolio, mainly driven by favorable pricing and a sustained family of products.
DVAPositive Net Change HAEPositive Net Change ALCPositive Net Change HIMSNegative Net Change
medical
Is a Beat Likely for Edwards Lifesciences (EW) in Q2 Earnings?
by Zacks Equity Research
Edwards Lifesciences' (EW) TMTT segment's PASCAL platform is likely to have maintained strong growth momentum in the second quarter globally, backed by its portfolio of differentiated therapies.
EWPositive Net Change GKOSPositive Net Change TNDMPositive Net Change EYENegative Net Change
earnings medical medical-devices
Enovis' (ENOV) New System to Aid Reverse Shoulder Prosthesis
by Zacks Equity Research
Enovis (ENOV) introduces the AltiVate Reverse Glenoid System, expanding the glenoid implant offering of the AltiVate Reverse to include modular, augmented baseplates.
UHSNegative Net Change SYKPositive Net Change DVAPositive Net Change ENOVNegative Net Change
medical medical-devices
Reasons to Retain Veeva Systems (VEEV) in Your Portfolio Now
by Zacks Equity Research
Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock. However, data security threats and escalating costs are a concern.
UHSNegative Net Change SYKPositive Net Change DVAPositive Net Change VEEVPositive Net Change
medical medical-devices
Best Momentum Stocks to Buy for July 15th
by Zacks Equity Research
TBPH, HGV, and SPT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 15, 2024.
TBPHNegative Net Change HGVPositive Net Change SPTPositive Net Change
medical
Legend Biotech (LEGN) Up 12% on Reports of Takeover Bid
by Zacks Equity Research
A third-party article suggests that Legend Biotech (LEGN) hired investment banking firm Centerview Partners to help its board review the takeover offer.
BMYPositive Net Change JNJNegative Net Change LEGNPositive Net Change TSVTNegative Net Change
biotechs cell-therapy medical pharmaceuticals
3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio Now
by Zacks Equity Research
Expanding product portfolio and high prospects for POC raise optimism for Inogen (INGN) stock.
UHSNegative Net Change ISRGPositive Net Change DXCMPositive Net Change INGNPositive Net Change
medical medical-devices
Take the Zacks Approach to Beat the Markets: NVIDIA, Twist Bioscience, Ollie's Bargain Outlet in Focus
by Santanu Roy
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
AMTNegative Net Change PSANegative Net Change NVDANegative Net Change LRCXNegative Net Change ORCLPositive Net Change ROLPositive Net Change OLLINegative Net Change VCYTNegative Net Change NOBLNegative Net Change TWSTPositive Net Change DDOGPositive Net Change OUSTNegative Net Change
business-services computers medical retail semiconductor
Is The Options Market Predicting A Spike In BioMarin Pharmaceutical (BMRN) Stock?
by Zacks Equity Research
Investors need to pay close attention to BioMarin Pharmaceutical (BMRN) stock based on the movements in the options market lately.
BMRNPositive Net Change
medical
Immutep (IMMP) Up as Combo Therapy Meets Carcinoma Study Goals
by Zacks Equity Research
Immutep (IMMP) jumps 15% on positive results from a late-stage study evaluating its candidate, efti, in combination with Keytruda to treat first-line head and neck squamous cell carcinoma patients.
MRKPositive Net Change IMMPNo Net Change ANVSNegative Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Quest Diagnostics (DGX) Set to Acquire OhioHealth's Lab Services
by Zacks Equity Research
Quest Diagnostics' (DGX) new agreement is likely to help expand access to cost-effective and advanced laboratory services in Ohio.
DGXNegative Net Change DVAPositive Net Change HAEPositive Net Change HIMSNegative Net Change
medical medical-devices
Implied Volatility Surging for Fennec (FENC) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Fennec (FENC) stock based on the movements in the options market lately.
FENCPositive Net Change
biotechnology biotechs medical
New Strong Buy Stocks for July 15th
by Zacks Equity Research
TEF, AY, CQP, TBPH, and VIRC have been added to the Zacks Rank #1 (Strong Buy) List on July 15, 2024.
TEFNegative Net Change VIRCPositive Net Change ALLTPositive Net Change TBPHNegative Net Change AYPositive Net Change
consumer-discretionary medical oil-energy
Can Elevance Health (ELV) Beat Q2 Earnings on Lower Expenses?
by Zacks Equity Research
Elevance Health's (ELV) second-quarter results are likely to be aided by improved product revenues, commercial fee-based membership growth, and lower expenses.
EWPositive Net Change CINegative Net Change CORNegative Net Change ELVNegative Net Change
medical
3 Reasons Why You Should Hold McKesson (MCK) Stock for Now
by Zacks Equity Research
McKesson's (MCK) robust Biologics business raises optimism about the stock.
ISRGPositive Net Change DVAPositive Net Change MCKPositive Net Change ELVNegative Net Change
medical medical-devices
Reasons to Retain Cardinal Health (CAH) in Your Portfolio Now
by Zacks Equity Research
Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.
UHSNegative Net Change SYKPositive Net Change DVAPositive Net Change CAHNegative Net Change
medical medical-devices
Roche Holding's (RHHBY) Accu-Chek SmartGuide Receives CE Mark
by Zacks Equity Research
Roche Holding (RHHBY) announces the receipt of CE Mark for its Accu-Chek SmartGuide CGM solution which is intended toward providing better diabetes management.
RHHBYNegative Net Change UHSNegative Net Change SYKPositive Net Change DVAPositive Net Change
medical medical-devices